Virion Therapeutics Reports Promising Results for HBV Functional Cure Therapy

VRON-0200 immunotherapy shows potential to 'spark' and re-awaken durable HBV-specific immunity in majority of chronically infected patients

Feb. 23, 2026 at 12:53am

Got story updates? Submit your updates here. ›

Virion Therapeutics announced at the CROI 2026 conference that a single dose of its VRON-0200 immunotherapy was able to 'spark' and re-awaken durable HBV-specific immunity in the majority of chronically HBV-infected patients, with HBsAg declines that were sustained or deepened through Day 360. The data also highlighted VRON-0200's favorable safety and tolerability profile, and its rapid and profound synergy when combined with antigen lowering antiviral agents.

Why it matters

These results represent an important milestone in the development of potential functional cures for chronic HBV, which has been limited by the inability of current treatments to restore a patient's own immune responses against the virus. VRON-0200 has the potential to prevent viral rebound after treatment discontinuation and improve overall functional cure rates.

The details

In the Phase 1b study, a single intramuscular dose of VRON-0200 was able to 'spark' and re-awaken durable HBV-specific immunity in the majority of chronically HBV-infected patients, with HBsAg declines that were sustained or deepened through Day 360. The data also showed VRON-0200's rapid and profound synergy when combined with antigen lowering antiviral agents, which could potentially shorten combination treatment regimens and expand the therapy to other patient populations.

  • The data was presented as a late breaker presentation at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, CO on February 23, 2026.

The players

Virion Therapeutics, LLC

A clinical-stage biotechnology company developing novel T cell-based immunotherapies that utilize checkpoint modifiers.

Dr. Sue Currie, PhD.

Presented the data on VRON-0200 at the CROI 2026 conference.

Dr. Andrew Luber, Pharm.D.

CEO of Virion Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We are now at a pivotal point in the development of potential functional cures for chronic HBV, with exciting progress being made, with different classes of HBV treatments. These treatments, however, are limited by their inability to restore a patient's own immune responses against the virus. As a result, once treatment is discontinued, viral rebound typically occurs in a large proportion of patients. The field now believes that immune modulators are necessary to mitigate this virological rebound.”

— Dr. Sue Currie, PhD. (CROI 2026)

“VRON-0200, Virion's first CPM-containing immunotherapy, with its favorable safety and tolerability profile, documented durable clinical activity, and convenient single i.m. administration, along with its potential for increased accessibility due to its ease of scalabilty and distribution, make it ideal for global public health initiatives.”

— Dr. Andrew Luber, Pharm.D., CEO of Virion Therapeutics (CROI 2026)

What’s next

A Phase 2b SPARK-B trial for HBV Functional Cure is in development and will use the 'Spark and Fan' approach to evaluate VRON-0200 in combination with investigational antivirals.

The takeaway

VRON-0200 represents a promising new immunotherapy that has the potential to restore a patient's own immune responses against chronic HBV, overcoming a key limitation of current treatments and paving the way for functional cures for this global health issue.